[Approach to benign hypertrophy of the prostate in primary health care].
Bentué Ferrer
C
C
Centro de Salud Delicias Sur, Zaragoza.
Córdoba García
R
R
D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use; D000726:Androgen Antagonists / Q000627:therapeutic use; D047072:Aromatase Inhibitors; D042944:Cholestenone 5 alpha-Reductase; D003937:Diagnosis, Differential; D006801:Humans; D008297:Male; D010088:Oxidoreductases / Q000037:antagonists & inhibitors; D008517:Phytotherapy; D011470:Prostatic Hyperplasia / Q000175:diagnosis / Q000628:therapy; D012307:Risk Factors
D000317:Adrenergic alpha-Antagonists; D000726:Androgen Antagonists; D047072:Aromatase Inhibitors; D010088:Oxidoreductases; D042944:Cholestenone 5 alpha-Reductase